References in Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) - The Lancet
Targets and action of ICIs ipilimumab, nivolumab, and pembrolizumab: A.... | Download Scientific Diagram
Mechanism of action of immune checkpoint inhibitors. Notes: T regs... | Download Scientific Diagram
Ipilimumab – mechanism of action and impact on advanced melanoma - ppt download
Frontiers | The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study | Oncology
Frontiers | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time | Immunology
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Synergism between CTLA-4 and PD-(L)1 inhibition: the nivolumab-ipilimumab story - BJMO
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
New modalities of cancer treatment for NSCLC: focus on immunotherapy | CMAR
Nivolumab en/of ipilimumab en totale overleving in gevorderd melanoom? - Skin
Ipilimumab – mechanism of action and impact on advanced melanoma - ppt download
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006 - Annals of Oncology
Home - UROONCO Kidney Cancer
Nivolumab (Opdivo) Drug Information
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies - ScienceDirect
Ipilimumab - Yervoy blijkt veilige en effectieve behandeling bij beginnende nog niet behandelde patienten met een melanoom.
Targeting Programmed Death-1 (PD-1) and Its Ligand (PD-L1) | Personalized Medicine in Oncology
Nieuwe behandelingen in de oncologie: immunotherapie en TKI s, veiligheid en interacties Een keerzijde van nieuwe immuuntherapieen? - PDF Free Download
Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab - ScienceDirect
Ipilimumab: Mode of Action Note. From " Ipilimumab: Controversies in... | Download Scientific Diagram
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial - The Lancet Oncology
Mechanism of Pembrolizumab / Nivolumab. (Reprinted from permission of... | Download Scientific Diagram
Special Issues | Value-Based Cancer Care
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings | RadioGraphics
Mechanism of action of nivolumab. | Download Scientific Diagram
